Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.33 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23728934 | 0.94 | KDM4E (0.33) | RPS6KA3P2RY12KDM4EMAPTNPSR1 | |
| SCHEMBL23728958 | 0.94 | KDM4E (0.33) | RPS6KA3P2RY12KDM4EMAPTNPSR1 | |
| SCHEMBL23728922 | 0.91 | HDAC1 (0.32) | HDAC1HDAC2HDAC8KDM4EMAPT | |
| SCHEMBL23728963 | 0.90 | P2RX3 (0.34) | P2RY12HDAC1HDAC2HDAC8KDM4E | |
| SCHEMBL23728940 | 0.89 | P2RY12 (0.31) | P2RY12 | |
| SCHEMBL23728901 | 0.89 | TOP1 (0.33) | HDAC1HDAC2HDAC8KDM4EMAPT | |
| SCHEMBL23728911 | 0.85 | MEN1 (0.33) | KDM4EMAPT | |
| SCHEMBL23728949 | 0.85 | MEN1 (0.33) | KDM4EMAPT | |
| SCHEMBL23728909 | 0.84 | RPS6KA3 (0.31) | RPS6KA3P2RY12HDAC1HDAC2HDAC8 | |
| SCHEMBL23728952 | 0.83 | P2RX3 (0.35) | KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384506-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2024-06-19 | — | — | EP | disclosed |
| WO-2023014793-A1 | PROCESS FOR POLYAMIDE SYNTHESIS | Design Therapeutics, Inc. (US) | 2023-02-09 | — | — | WO | disclosed |
| EP-4100404-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021158707-A1 | METHODS AND COMPOUNDS FOR THE TREATMENT OF GENETIC DISEASE | Design Therapeutics, Inc. (US) | 2021-08-12 | — | — | WO | disclosed |